Bet1 Inhibitors
The class of Bet1 Inhibitors would encompass a range of chemicals that indirectly interfere with the normal function of Bet1 by targeting various cellular mechanisms and signaling pathways associated with vesicle formation and trafficking between the endoplasmic reticulum and Golgi apparatus. These inhibitors could act at different stages of the vesicular transport pathway, from the initiation of vesicle budding to the final fusion with the target membrane.
The indirect inhibition of Bet1 can occur through several mechanisms. Compounds could target the regulatory proteins such as small GTPases (e.g., Sar1 and ARF) that are critical for vesicle formation and coat recruitment, thus preventing the proper functioning of the COPII and COPI vesicle coats. Other compounds might interact with proteins that modulate the vesicle scission process or with those involved in the tethering and docking at the Golgi apparatus. Additionally, some chemicals might interfere with the post-translational modifications of proteins, such as glycosylation, that are necessary for the proper sorting and functioning of proteins involved in vesicular trafficking. Others could alter intracellular signaling cascades that indirectly modulate vesicle formation and trafficking, affecting Bet1's role in these processes. Each chemical in this class would have a distinct mode of action, ranging from the inhibition of protein-protein interactions essential for vesicle coat assembly to the disruption of normal organelle function, such as that of the Golgi apparatus, which would be essential for Bet1-mediated transport.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Acts by inhibiting ADP-ribosylation factor (ARF), a GTPase that recruits coat proteins to membranes; this disrupts vesicle formation and can indirectly inhibit Bet1's role in transport. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A dynamin inhibitor that blocks the GTPase activity of dynamin, interfering with vesicle scission from the Golgi, indirectly affecting Bet1-dependent trafficking. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
Reacts with and modifies cysteine residues on proteins, potentially altering the function of SNARE proteins that interact with Bet1. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
A monovalent cation ionophore that disrupts Golgi function and can indirectly inhibit Bet1 by altering Golgi pH and cation homeostasis. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, disrupting normal protein folding and function in the ER, thereby potentially affecting Bet1 function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Specifically targets the Golgi BFA resistance factor 1 (GBF1), an ARF-GEF, disrupting ARF-mediated recruitment of coat proteins and indirectly affecting Bet1. | ||||||
Guanabenz HCl | 23113-43-1 | sc-507500 | 100 mg | $246.00 | ||
Originally an antihypertensive drug, it can affect the unfolded protein response and thus indirectly influence ER-Golgi traffic where Bet1 is involved. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
A protein kinase A inhibitor that may indirectly affect various proteins, including those involved in vesicular trafficking pathways involving Bet1. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits glycogen synthase kinase 3, which may have downstream effects on vesicular trafficking and indirectly on Bet1 function. | ||||||